Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
Krista Kinneer, Philipp Wortmann, Zachary A. Cooper, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 6, pp. 1086-1101
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Raffaele Colombo, Paolo Tarantino, Jamie R. Rich, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2089-2108
Closed Access | Times Cited: 19
Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
Weining Weng, Tao Meng, Qianqian Zhao, et al.
Cancer Discovery (2023) Vol. 13, Iss. 4, pp. 950-973
Open Access | Times Cited: 37
A Review of Protein- and Peptide-Based Chemical Conjugates: Past, Present, and Future
Emily Holz, Martine Darwish, Devin B. Tesar, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 600-600
Open Access | Times Cited: 30
New Life of Topoisomerase I Inhibitors as Antibody–Drug Conjugate Warheads
Yves Pommier, Anish Thomas
Clinical Cancer Research (2023) Vol. 29, Iss. 6, pp. 991-993
Open Access | Times Cited: 23
Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates
Mark E. Petersen, Michael G. Brant, Manuel Lasalle, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 5, pp. 606-618
Open Access | Times Cited: 10
Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance
Jiali Yu, Yijian Yan, Shasha Li, et al.
Cell (2024) Vol. 187, Iss. 17, pp. 4713-4732.e19
Open Access | Times Cited: 8
Extensive Biotransformation Profiling of AZD8205, an Anti-B7-H4 Antibody-Drug Conjugate, Elucidates Pathways Underlying Its Stability In Vivo
Yue Huang, Hui Yin Tan, Jiaqi Yuan, et al.
Analytical Chemistry (2024) Vol. 96, Iss. 42, pp. 16525-16533
Open Access | Times Cited: 6
Update on Combination Strategies of PARP Inhibitors
Zhuoqun Lin, Lingfang Wang, Ziyu Xing, et al.
Cancer Control (2024) Vol. 31
Open Access | Times Cited: 6
SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models
Elizabeth Gray, Michelle Ulrich, Angela Epp, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 10, pp. e007572-e007572
Open Access | Times Cited: 14
Extensive Biotransformation Profiling of AZD8205, an Anti-B7-H4 Antibody-Drug Conjugate, Elucidates Pathways Underlying its Stability In Vivo
Yue Huang, Hui Yin Tan, Jiaqi Yuan, et al.
(2024)
Open Access | Times Cited: 5
Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors
Luana Guimarães de Sousa, Daniel J. McGrail, Felippe Lazar Neto, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 16, pp. 3162-3171
Open Access | Times Cited: 13
AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
Weining Weng, Tao Meng, Junyi Pu, et al.
Molecular Cancer Therapeutics (2023) Vol. 22, Iss. 9, pp. 1013-1027
Open Access | Times Cited: 11
A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE
Yichen Wang, Yanyang Nan, Chunguang Ma, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 4
Open Access | Times Cited: 4
The clinical landscape of antibody-drug conjugates in endometrial cancer
Giovanni Fucá, Ilaria Sabatucci, Mariachiara Paderno, et al.
International Journal of Gynecological Cancer (2024) Vol. 34, Iss. 11, pp. 1795-1804
Closed Access | Times Cited: 4
A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective
Yuxi Zhao, Hua Yuan, Ning Li, et al.
International Journal of Biological Macromolecules (2025), pp. 140767-140767
Closed Access
Effects of PARP1 inhibitor PJ-34 on TGFα, IL-6, and IL-1β levels in diabetic nephropathy
Jing Ke, Yanan Fan, Shaochun Zhang
The Journal of Immunology (2025)
Closed Access
Development of Antibody–Drug Conjugates for Malignancies of the Uterine Corpus: A Review
T. Yamanaka, Tadaaki Nishikawa, Hiroshi Yoshida
Cells (2025) Vol. 14, Iss. 5, pp. 333-333
Open Access
B7-H4 Protein Expression in Endometrial Cancer
Bobby L. May, Nicholas Conway, Tracy Truong, et al.
(2025)
Closed Access
B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review
Marion Phipps, Gerald S. Falchook
Journal of Immunotherapy and Precision Oncology (2025) Vol. 8, Iss. 2, pp. 153-160
Open Access
A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Sarah B. Gitto, Margaret Whicker, Gareth Davies, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 8, pp. 1567-1581
Open Access | Times Cited: 10
Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression
Christina Vasalou, Theresa A. Proia, Laura Kazlauskas, et al.
CPT Pharmacometrics & Systems Pharmacology (2024) Vol. 13, Iss. 6, pp. 994-1005
Open Access | Times Cited: 3
LINC01235 Promotes Clonal Evolution through DNA Replication Licensing‐Induced Chromosomal Instability in Breast Cancer
Qi Zhang, Xuliren Wang, Zhibo Shao, et al.
Advanced Science (2025)
Open Access
Reinventing chemotherapy
Bruce A. Chabner, Jacob Gehri, Beatrix Thompson
The Oncologist (2025) Vol. 30, Iss. 2
Open Access
Double Agents in Immunotherapy: Unmasking the Role of Antibody Drug Conjugates in Immune Checkpoint Targeting
Sruthi Ranganathan, Aswanth Reddy, Alessandro Russo, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 202, pp. 104472-104472
Closed Access | Times Cited: 3
Antibody–Drug Conjugates: Advancing from Magic Bullet to Biological Missile
Ana Veneziani, Suku Sneha, Amit M. Oza
Clinical Cancer Research (2024) Vol. 30, Iss. 8, pp. 1434-1437
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top